- Report
- February 2024
- 250 Pages
Global
From €4767EUR$5,000USD£4,073GBP
- Report
- November 2023
- 144 Pages
Global
From €2383EUR$2,499USD£2,036GBP
- Clinical Trials
- February 2024
- 180 Pages
Global
From €2860EUR$3,000USD£2,444GBP
- Report
- July 2023
- 218 Pages
Global
From €4290EUR$4,500USD£3,666GBP
- Report
- October 2023
- 145 Pages
Global
From €3003EUR$3,150USD£2,566GBP
- Report
- March 2024
- 221 Pages
Global
From €3432EUR$3,600USD£2,933GBP
- Report
- March 2024
- 121 Pages
Europe
From €1430EUR$1,500USD£1,222GBP
- Report
- March 2024
- 122 Pages
Asia Pacific
From €1430EUR$1,500USD£1,222GBP
- Report
- March 2024
- 112 Pages
North America
From €1430EUR$1,500USD£1,222GBP
- Report
- March 2024
- 121 Pages
Middle East, Africa
From €1430EUR$1,500USD£1,222GBP
- Report
- October 2020
- 156 Pages
Global
From €1311EUR$1,375USD£1,120GBP
€2622EUR$2,750USD£2,240GBP
- Report
- October 2022
- 270 Pages
Global
From €3575EUR$3,750USD£3,055GBP
- Report
- August 2020
- 112 Pages
Global
From €4052EUR$4,250USD£3,462GBP
- Report
- September 2022
- 282 Pages
Global
From €9058EUR$9,500USD£7,739GBP
- Report
- September 2022
- 141 Pages
Global
From €4529EUR$4,750USD£3,869GBP
- Report
- January 2023
- 116 Pages
Global
From €4290EUR$4,500USD£3,666GBP
- Report
- April 2018
Global
From €4290EUR$4,500USD£3,666GBP
- Report
- August 2022
United States
From €1850EUR$1,940USD£1,580GBP
- Report
- August 2022
Global
From €944EUR$990USD£806GBP
- Report
- February 2021
Global
From €2822EUR$2,960USD£2,411GBP
Psoriatic Arthritis Drug is a type of drug used to treat psoriatic arthritis, a type of immune disorder. It is a chronic, inflammatory condition that affects the joints and skin. Psoriatic Arthritis Drug works by targeting the underlying cause of the disease, which is an overactive immune system. It helps to reduce inflammation and pain, and can also slow down the progression of the disease. Commonly used Psoriatic Arthritis Drugs include biologics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs).
The Psoriatic Arthritis Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of psoriatic arthritis, as well as the development of new and more effective treatments. The market is expected to continue to grow in the coming years, as more treatments become available and the demand for them increases.
Some of the major companies in the Psoriatic Arthritis Drug market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and Roche. Show Less Read more